ESR1 and breast carcinoma: Unfortunately, 30% of patients with ER positive (ER (+)) disease experience recurrence and metastasis, and there is a consistent long-term risk of death due to recurrent breast cancer with an even greater risk after 7 years [3,4,5,6,7].